HUGE! The Chairman’s Update explicitly states:
“As a result, the Company reported a small profit for calendar year 2025.”
Why This Profit Matters More Than Its Size
Even a tiny profit is strategically significant for a microcap like BIEL. Here’s why:
1. It proves operational discipline
The Chairman notes that profitability came from:
Office relocation
Staff reduction
This shows BIEL can control costs — a major hurdle for early‑stage medical device companies.
2. It activates the $41M tax‑loss carryforward engine
Once a company becomes profitable, tax-loss carryforwards begin shielding future profits from taxes. It validates the long-discussed $41M tax-loss carryforward strategy: once profitable, margins accelerate.
This means:
Future profits convert almost directly into net income
Profitability scales faster than revenue
PPS sensitivity to profit increases dramatically
This is why even a small profit is a major inflection point.
3. It signals BIEL has crossed the “viability threshold”
Microcaps often hover in perpetual losses.
A single profitable year — even modest — signals:
The business model works
Cash burn is under control
The company can sustain operations
Investors can begin valuing the company on earnings rather than survival
This update is the strongest strategic communication BIEL has released in years.
4. It sets the stage for profit‑driven PPS revaluation
Profitability — even small — is a psychological and financial turning point for microcaps.
Once a microcap becomes profitable:
Investors begin applying P/E multiples
Even small profit increases can move PPS sharply
Profit milestones (e.g., $250K, $500K, $1M) become meaningful valuation triggers
This ties directly into the broader modeling of:
$250K profit = copper PPS
Each $250K increment = +.01 PPS
Profitability is the prerequisite for that entire valuation framework.
What Likely Drove the Profit
Based on the Chairman’s letter, the profit likely came from:
A. Cost reductions
Office relocation
Staff reduction
B. Steady revenue base
The Chairman confirms:
“An increase in monthly sales, both in the OTC and professional markets.”
This means:
Revenue was stable or growing
Costs dropped
Profit emerged naturally
C. No major one‑time expenses
The letter does not mention:
Write‑downs
Inventory losses
Litigation costs
Manufacturing disruptions
This suggests the profit was operational, not artificial.
Why Profitability Now Is Perfectly Timed
Profitability in 2025 sets the stage for 2026–2027 catalysts:
1. Electrome execution
Purchase order received, manufacturing underway.
This is the largest distribution channel BIEL has ever had.
2. Monthly sales growth already confirmed
3. NO PAIN Act clinical pathway active
4. Professional advertising launched
5. Consumer advertising expanded
Profitability + sales growth + Electrome + NO PAIN Act =
A multi‑channel profit expansion cycle.
Bottom Line
BIEL’s “small profit” has HUGE impact.
It is:
A validation of the business model
A trigger for tax‑loss leverage
A signal of operational maturity
A foundation for profit‑driven PPS revaluation
A setup for Electrome’s commercial launch
A psychological milestone for investors
A turning point!
“As a result, the Company reported a small profit for calendar year 2025.”
Why This Profit Matters More Than Its Size
Even a tiny profit is strategically significant for a microcap like BIEL. Here’s why:
1. It proves operational discipline
The Chairman notes that profitability came from:
Office relocation
Staff reduction
This shows BIEL can control costs — a major hurdle for early‑stage medical device companies.
2. It activates the $41M tax‑loss carryforward engine
Once a company becomes profitable, tax-loss carryforwards begin shielding future profits from taxes. It validates the long-discussed $41M tax-loss carryforward strategy: once profitable, margins accelerate.
This means:
Future profits convert almost directly into net income
Profitability scales faster than revenue
PPS sensitivity to profit increases dramatically
This is why even a small profit is a major inflection point.
3. It signals BIEL has crossed the “viability threshold”
Microcaps often hover in perpetual losses.
A single profitable year — even modest — signals:
The business model works
Cash burn is under control
The company can sustain operations
Investors can begin valuing the company on earnings rather than survival
This update is the strongest strategic communication BIEL has released in years.
4. It sets the stage for profit‑driven PPS revaluation
Profitability — even small — is a psychological and financial turning point for microcaps.
Once a microcap becomes profitable:
Investors begin applying P/E multiples
Even small profit increases can move PPS sharply
Profit milestones (e.g., $250K, $500K, $1M) become meaningful valuation triggers
This ties directly into the broader modeling of:
$250K profit = copper PPS
Each $250K increment = +.01 PPS
Profitability is the prerequisite for that entire valuation framework.
What Likely Drove the Profit
Based on the Chairman’s letter, the profit likely came from:
A. Cost reductions
Office relocation
Staff reduction
B. Steady revenue base
The Chairman confirms:
“An increase in monthly sales, both in the OTC and professional markets.”
This means:
Revenue was stable or growing
Costs dropped
Profit emerged naturally
C. No major one‑time expenses
The letter does not mention:
Write‑downs
Inventory losses
Litigation costs
Manufacturing disruptions
This suggests the profit was operational, not artificial.
Why Profitability Now Is Perfectly Timed
Profitability in 2025 sets the stage for 2026–2027 catalysts:
1. Electrome execution
Purchase order received, manufacturing underway.
This is the largest distribution channel BIEL has ever had.
2. Monthly sales growth already confirmed
3. NO PAIN Act clinical pathway active
4. Professional advertising launched
5. Consumer advertising expanded
Profitability + sales growth + Electrome + NO PAIN Act =
A multi‑channel profit expansion cycle.
Bottom Line
BIEL’s “small profit” has HUGE impact.
It is:
A validation of the business model
A trigger for tax‑loss leverage
A signal of operational maturity
A foundation for profit‑driven PPS revaluation
A setup for Electrome’s commercial launch
A psychological milestone for investors
A turning point!
2
